NCT07657299Completed
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
Bladder cancer is common tumor in which recurrence and/or progression in patients undergoing TUR has been reported to range between 30% and 80% in patients with NMIBC TCC. With evidence of E-cadherin, β-catenin and SOX4 playing a role in the development of tumors, it manifests as invasion and metastasis. In this study, we hope to develop the correlation regarding the alternation in the expression of E-cadherin, β-catenin and Sox4 in determining the recurrence, progression and up staging and their prognostic value in NMIBC.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 13 Jun 2026
- Start date
- 1 Apr 2022
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Ain Shams University
- Diseases
- Bladder cancer, Childhood cancers
- NCT number
- NCT07657299
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 1 Apr 2022 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- 1\. The patients were treated with transurethral resection of bladder tumor finally diagnosed with NMIBC TCC by pathological examination.
- 2\. The controls were normal bladder tissues. Or patients diagnosed with cystitis or dysplasia on pathological examination
- \- Exclusion Criteria:
- Age at the time of cancer diagnosis \> 70 years
- Patients diagnosed with MIBC
- Patients with concomitant upper urinary tracts tumors
- Patients with concomitant prostatic tumors
- Patients diagnosed with TCC T1 who did not received full induction, or maintenance doses BCG
- Patients showed BCG toxicity signs
- Patients diagnosed with TCC T1 who did not underwent 2nd look TURBT
- Patients with known genetic/congenital disorder that may interfere with/or increase risk of BC;
- Bladder exstrophy.
- Rb1: An altered form of Rb1, retinoblastoma gene, is associated with cancer of the eye in infants, and may increase your bladder cancer risks.
- Cowden disease: This syndrome, linked to an abnormal form of the gene PTEN, may trigger breast cancer and thyroid cancer, and increases the risk of bladder cancer.
- Lynch syndrome: This genetic condition, also known as hereditary non-polyposis colorectal cancer, is usually tied to colon and endometrial cancer. However, this syndrome may also increase the risk of bladder cancer and cancer of the ureter.
- Patients with history of chemotherapy or pelvic radiations for other tumor treatment than BC
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine-Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.